Clinical Trials Logo

Polyneuropathies clinical trials

View clinical trials related to Polyneuropathies.

Filter by:

NCT ID: NCT05165368 Recruiting - Clinical trials for Diabetic Neuropathy, Distal Symmetric Polyneuropathy (Manifestation)

Effect of Gluten-Free Dietary Education and Intraneural Facilitation® Therapy on Quality of Life in People With Diabetic Neuropathy

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to compare the effectiveness of providing dietary education to complement Intraneural Facilitation® Therapy (INF® Therapy) (a physical therapy technique being evaluated that may help improve circulation) versus INF® Therapy only in adults with a type of neuropathy called distal symmetric polyneuropathy (DSPN).

NCT ID: NCT05071300 Recruiting - Clinical trials for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Start date: January 4, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of extended dosing with Eplontersen in participants with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).

NCT ID: NCT05040373 Recruiting - Polyneuropathy Clinical Trials

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Start date: August 1, 2020
Phase:
Study type: Observational

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

NCT ID: NCT05023889 Recruiting - Clinical trials for Transthyretin Amyloidosis

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Start date: August 3, 2022
Phase: Early Phase 1
Study type: Interventional

To evaluate the efficacy and safety of patisiran in patients with wtATTR amyloidosis and symptomatic polyneuropathy by evaluating the effect on neurologic impairment and quality of life.

NCT ID: NCT05011006 Recruiting - Clinical trials for Peripheral Neuropathy

NT-3 Levels and Function in Individuals With CMT

Start date: November 13, 2019
Phase:
Study type: Observational

This study will assess the serum NT-3 levels in individuals with the diagnosis of peripheral neuropathy or any type of Charcot-Marie-Tooth Neuropathy (CMT) and correlate this with function.

NCT ID: NCT04963985 Recruiting - Clinical trials for Transthyretin Amyloidosis

The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients

Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Transthyretin amyloid polyneuropathy (ATTR-PN) is a fatal illness resulting from autosomal dominantly inherited single-point mutations on the transthyretin gene. Tafamidis is a specific stabilizer of both variant and wild-type TTR. Tafamidis binds to TTR at the thyroxine binding sites and inhibits TTR tetramer dissociation, the rate limiting step in the amyloidogenic process. The result disrupts the amyloid cascade and fibril formation and interrupts disease progression. This study provides the basis for the study of the effect of tafamidis on the stability of transthyretin and its safety, tolerance and efficacy in patients with transthyretin amyloid polyneuropathy.

NCT ID: NCT04929236 Recruiting - Clinical trials for Pediatric Chronic Inflammatory Demyelinating Polyneuropathy

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Start date: October 1, 2023
Phase: Phase 3
Study type: Interventional

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

NCT ID: NCT04881682 Recruiting - CIDP Clinical Trials

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

IVITOC
Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

NCT ID: NCT04699734 Recruiting - Neuropathic Pain Clinical Trials

Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy

Start date: September 8, 2020
Phase: N/A
Study type: Interventional

The purpose of the present study is to evaluate the role of peripheral afferent input for spontaneous pain in painful diabetic polyneuropathy

NCT ID: NCT04672733 Recruiting - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

pHeNIx
Start date: June 10, 2022
Phase:
Study type: Observational

The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).